CanWell Pharma will update company’s ADC programs at ADC & Novel Conjugates Partnering & Investment Summit held on September 9-10, 2025 in Boston. It covers newest research updates on StarLinker dual/tri-payload ADCs, which had been making tremendous progress in preclinical efficacy studies …

CanWell Pharma will present the latest research developments at the 39th of The Society for Immunotherapy of Cancer (SITC) Annual Meeting held on Nov6-10, 2024 in Houston, TX. The research developments are from its two different studies and will be conducted on the following two posters: Date: Nov8,…

CanWell Pharma will present its latest research developments at the 15th World ADC in San Diego, CA held on Nov 5-7, 2024. The presentation will be conducted on a poster during Poster Session of the conference. The poster covers newest research updates on Dual-Payload ADCs, which may make significan…

Read More (click to read the original article)

CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA). CanWell plans to immediately initiate the patient enrollment to evaluate CAN2109’s safety, PK, PD and clinical activity for the treat…